https://europeanatolia.com/index.php/pub <p><strong>E-ISSN: 2980-3861</strong></p> <p><strong>Journal name: </strong>Europeanatolia Health Sciences Journal</p> <p><strong>Start:</strong> 2023 (ROAD)</p> <p><strong>Publication language:</strong> English (From 2025 onwards)</p> <p><strong>Publication period: </strong>Three issues per year (Every four months) (April, August and December). It can also publish special or additional issues.</p> <p><strong>Publication type: </strong>Research article, reviews, case report, letter to the editor, research note, abstract or book critic.</p> <p><strong>Publication topics: </strong>Medical Sciences (Medicine), Dentistry, Veterinary Medicine, Pharmacy, Perfusion, Midwifery, Nursing, Nutrition and Dietetics, Child Development, Speech and Language Therapy, Occupational Therapy, Physiopathology, Physiotherapy and Rehabilitation, Audiology, Neuroscience, Toxicology, Molecular Medicine, CBRN (Chemical, Biological, Radiological, Nuclear), Health Informatics, Health Economics, Health Physics, Health Management, Social Work, Sociology, Psychology, Emergency Aid and Disaster Management, Occupational Health and Safety, Orthotics-Prosthetics, Gerontology, Biology, Chemistry, Molecular Biology and Genetics, Biotechnology and other health science fields.</p> <p><strong>Europeanatolia Health Sciences Journal </strong>is a double-blind, peer-reviewed, scientific, academic, open access and online journal.</p> <p>This journal is published by BAP ACADEMY.</p> <p><strong>Indexing &amp; Abstracting</strong>: Europeanatolia Health Sciences Journal is included in many national and international indexes. For the list of indexes, click on the indexes <strong><a href="https://europeanatolia.com/index.php/pub/indexing">tab.</a></strong></p> Bişar Amaç en-US Europeanatolia Health Sciences Journal 2980-3861 https://europeanatolia.com/index.php/pub/article/view/52 <p><strong>Objective: </strong> No study has evaluated AAV's lung prognosis and the Vasculitis Damage Index (VDI). This study investigated lung involvement in AAV-associated disease activity, morbidity, and mortality rate.</p> <p><strong>Method: </strong>This retrospective analysis included 51 cases who were followed up in our institution's rheumatology outpatient clinic and diagnosed with AAV according to ARC and/or CHCC criteria. The patients were supposed to have lung <em>(pulmonary)</em> involvement at the beginning of the disease. Initial Birmingham Vasculitis Activity Scores <em>(BVAS)</em> and imaging findings were noted. Respiratory function test <em>(PFT),</em> 6-minute walk test <em>(6MWT)</em>, thorax CT findings, and vasculitis damage index <em>(VDI) </em>scores were recorded.</p> <p><strong>Results: </strong>ANCA positivity was detected in 94% of patients with AAV <em>(66% C-ANCA/anti-PR3, 34% p-ANCA/anti-MPO).</em> The total follow-up period was recorded as 66.5±52 months. Initial total and BVAS were calculated as 22±7 and 4.6±2.8. BVAS findings were determined as 80% nodule/cavity, 56% infiltration, 24% AH/massive hemoptysis, 11% respiratory failure, 5% pleural effusion/pleurisy, and 3% endobronchial involvement. Radiological improvement was seen in 35%, regression in 12%, progression in 12%, and sequela changes in 30% of the patients. Cumulative VHI and lung VHI scores were calculated as 3.5±2.3 and 0.5±0.8. The frequency of VHI findings was 22% lung function disorder, 8% lung fibrosis, 6% chronic dyspnea, 4% chronic asthma, and 2% pulmonary hypertension. Serious pulmonary infections were seen in 44% <em>(27% had &gt;1 severe infection)</em>. VHI was higher in those with serious pulmonary infections <em>(p=0.006)</em>.</p> <p><strong>Conclusion: </strong>Lung involvement with AAV causes high rates of lung damage and increased mortality in long-term follow-up.</p> Esra Aydın Sevil Kamacı Copyright (c) 2025 Europeanatolia Health Sciences Journal https://creativecommons.org/licenses/by/4.0 2025-08-10 2025-08-10 3 2 51 61 10.5281/zenodo.15834958